PTC Therapeutics Inc (PTCT)

20.27
0.14 0.69
NASDAQ : Health Care
Prev Close 20.41
Open 20.50
Day Low/High 19.80 / 20.71
52 Wk Low/High 5.27 / 60.93
Volume 532.78K
Avg Volume 629.60K
Exchange NASDAQ
Shares Outstanding 41.39M
Market Cap 844.75M
EPS -4.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

No Good Stock Left Behind: Cramer's 'Mad Money' Recap (Tuesday 7/25/17)

No Good Stock Left Behind: Cramer's 'Mad Money' Recap (Tuesday 7/25/17)

Jim Cramer says some sellers are making a big mistake by not giving top-notch CEOs the benefit of the doubt despite earnings upheaval.

Hertz Global Holdings, Honeywell, PetMed Express, Allergan: 'Mad Money' Lightning Round

Hertz Global Holdings, Honeywell, PetMed Express, Allergan: 'Mad Money' Lightning Round

Jim Cramer is bullish on Hertz Global Holdings, Honeywell, PetMed Express, and Allergan.

Preliminary Phase 2 Data From Spinal Muscular Atrophy Program Presented At CureSMA Conference

Preliminary Phase 2 Data From Spinal Muscular Atrophy Program Presented At CureSMA Conference

-- RG7916 demonstrated ~400% increase in SMN2 full length/¿7 mRNA ratio --

Commit To Buy PTC Therapeutics At $15, Earn 33.1% Annualized Using Options

Commit To Buy PTC Therapeutics At $15, Earn 33.1% Annualized Using Options

Investors considering a purchase of PTC Therapeutics Inc stock, but tentative about paying the going market price of $18.52/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $15 strike, which has a bid at the time of this writing of $2.80.

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Albany Molecular Research, Acorda Therapeutics and PTC Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

PTC Therapeutics Announces FDA Advisory Committee Meeting For Ataluren For The Treatment Of Nonsense Mutation Dystrophinopathy

- September 28th is FDA's Tentative Date for Advisory Committee Meeting -

Short Interest In PTC Therapeutics Expands By 20.8%

The most recent short interest data has been released for the 05/15/2017 settlement date, which shows a 1,263,458 share increase in total short interest for PTC Therapeutics Inc , to 7,350,209, an increase of 20.76% since 04/28/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

PTCT Crosses Above Average Analyst Target

In recent trading, shares of PTC Therapeutics Inc have crossed above the average analyst 12-month target price of $12.40, changing hands for $12.59/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Commit To Buy PTC Therapeutics At $8, Earn 26% Annualized Using Options

Investors eyeing a purchase of PTC Therapeutics Inc stock, but tentative about paying the going market price of $8.55/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $8 strike, which has a bid at the time of this writing of $1.70.

Biotech Premarket Movers: Seres, PTC, Inovio

Biotech Premarket Movers: Seres, PTC, Inovio

Seres Therapeutics, PTC Therapeutics and Inovio Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

PTC Therapeutics Announces Agreement To Acquire Emflaza™ For The Treatment Of Duchenne Muscular Dystrophy In U.S.

- Emflaza is the first treatment approved in the U.S. for DMD patients 5 years and older, regardless of genetic mutation

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Biotech Premarket Movers: PTC, Teligent, Minerva

Biotech Premarket Movers: PTC, Teligent, Minerva

PTC Therapeutics, Teligent and Minerva Neurosciences were among the biotech stock movers in premarket trading on Monday.

TheStreet Quant Rating: D (Sell)